Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
168.5 USD | +0.26% |
|
+0.35% | +8.82% |
12/07 | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
12/07 | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.82% | 30TCr | |
+62.68% | 86TCr | |
+38.95% | 63TCr | |
-4.01% | 36TCr | |
+15.81% | 32TCr | |
+5.89% | 23TCr | |
+16.53% | 23TCr | |
+15.61% | 18TCr | |
+1.77% | 16TCr | |
+2.41% | 13TCr |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcript : AbbVie Inc., Q4 2018 Earnings Call, Jan 25, 2019